Oppenheimer Analysts Give Bioline RX (BLRX) a $3.00 Price Target

Oppenheimer set a $3.00 target price on Bioline RX (NASDAQ:BLRX) in a research report released on Monday, December 4th. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also recently weighed in on BLRX. Zacks Investment Research raised Bioline RX from a hold rating to a buy rating and set a $1.25 price objective for the company in a research report on Tuesday, October 3rd. HC Wainwright set a $4.00 price objective on Bioline RX and gave the stock a buy rating in a research report on Wednesday, August 9th. Roth Capital set a $3.00 price objective on Bioline RX and gave the stock a buy rating in a research report on Wednesday, August 9th. Maxim Group set a $3.00 price objective on Bioline RX and gave the stock a buy rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised Bioline RX from a strong sell rating to a sell rating in a research report on Thursday, November 30th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $2.88.

Bioline RX (NASDAQ:BLRX) traded up $0.01 during trading on Monday, hitting $1.09. The stock had a trading volume of 493,686 shares, compared to its average volume of 521,009. The firm has a market cap of $113.47, a PE ratio of -3.30 and a beta of 0.89. Bioline RX has a 52-week low of $0.80 and a 52-week high of $1.38.

A hedge fund recently raised its stake in Bioline RX stock. KCG Holdings Inc. boosted its position in shares of Bioline RX Ltd (NASDAQ:BLRX) by 715.9% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 175,156 shares of the biotechnology company’s stock after acquiring an additional 153,687 shares during the quarter. KCG Holdings Inc. owned about 0.28% of Bioline RX worth $168,000 at the end of the most recent reporting period. 36.96% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Oppenheimer Analysts Give Bioline RX (BLRX) a $3.00 Price Target” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2017/12/30/oppenheimer-analysts-give-bioline-rx-blrx-a-3-00-price-target.html.

About Bioline RX

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for Bioline RX (NASDAQ:BLRX)

Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply